Interleukin-1 (IL-1), a cytokine produced by bone marrow cells and bone cells, has been implicated in the pathogenesis of postmenopausal osteoporosis because of its potent stimulatory effects on bone resorption in vitro and in vivo. To investigate whether IL-1 plays a direct causal role in post ovariectomy bone loss, 6-mo-old ovariectomized rats were treated with subcutaneous infusions ofIL-1 receptor antagonist (IL-ira), a specific competitor of IL-1, for 4 wk, beginning either at the time of surgery or 4 wk after ovariectomy. The bone density of the distal femur was measured non invasively by dual-energy X-ray absorptiometry. Bone turnover was assessed by bone histomorphometry and by measuring serum osteocalcin, a marker of bone formation, and the urinary excretion of pyridinoline crosslinks, a marker of bone resorption. Ovariectomy caused a rapid increase in bone turnover and a marked decrease in bone density which were blocked by treatment with 17,8 estradiol. Ovariectomy also increased the production of IL-i from cultured bone marrow cells. Ovariectomy induced bone loss was significantly decreased by IL-ira treatment started at the time of ovariectomy and completely blocked by IL-ira treatment begun 4 wk after ovariectomy. In both studies IL-ira also decreased bone resorption in a manner similar to estrogen, while it had no effect on bone formation. In contrast, treatment with IL-ira had no effect on the bone density and the bone turnover of sham-operated rats, indicating that IL-ira specifically blocked estrogen-dependent bone loss. In conclusion, these data indicate that IL-i, or mediators induced by IL-i, play an important causal role in the mechanism by which ovariectomy induces bone loss in rats, especially following the immediate post ovariectomy period. (J. Clin. Invest. 1994Invest. . 93:1959Invest. -1967
Introduction
Postmenopausal osteoporosis is a disorder characterized by a progressive loss of bone tissue which begins after natural or surgical menopause and leads to the occurrence of spontane-ous fractures (1) . Although the causal role of estrogen deficiency in this condition is well established (2) (3) (4) , the mechanism by which estrogen prevents bone loss is still conjectural at best. One such mechanism may be a modulatory effect on the secretion offactors that are produced in the bone microenvironment and influence bone remodeling (5) . Among them is IL-1, a family of cytokines (6) best known for its involvement in inflammation and wound healing (7, 8) , which is also recognized for its effects on bone remodeling. IL-l stimulates bone resorption in vitro (9, 10) and in vivo (1 1, 12) and induces hypercalcemia when injected into normal mice ( 13) by stimulating the activity of mature osteoclasts ( 14) and the differentiation of osteoclast precursors ( 15 ). Studies have also shown that IL-l inhibits bone formation in vitro ( 16) and in vivo ( 17) and induces bone cells to secrete several cytokines such as , TNFa( 15), andM-CSF( 19),whichregulatetheproliferation of osteoclast precursor cells and their differentiation into active osteoclasts.
A role for IL-I in postmenopausal bone loss is supported by recent studies showing that the expression of IL-I mRNA is increased in bone cells from postmenopausal women (20) and by previous observations from us (21, 22) and others (23, 24) demonstrating that both natural and surgical menopause are associated with an increased production of IL-I bioactivity from cultured monocytes that is blocked by estrogen replacement. However, the relevance of these findings with respect to the mechanism by which estrogen prevents bone loss has been difficult to elucidate, because estrogen regulates the production of several cytokines with overlapping effects on bone remodeling (25, 26) .
Recently, a specific human IL-l receptor antagonist (ILlra)' has been cloned and expressed in Escherichia coil with production of a recombinant 1 7-kD protein which shares 26% sequence homology with IL-lIW (27, 28) . IL-Ira binds to IL-1 receptors and competes with both IL-la and IL-lI without detectable IL-l agonistic effects (29, 30) . Human IL-lra has provided a tool for blocking the effects ofIL-1 in several rat cell types (31, 32) including bone cells (33) and to investigate the role of IL-l in many diseases (34) .
We have now assessed the effects ofIL-Ira on bone mineral density (BMD) and bone turnover in ovariectomized rats to investigate the role of IL-l in the bone loss caused by estrogen deficiency.
Methods
Studyprotocol. Two experiments were conducted in 6-mo-old nulliparous rats (Harlan Sprague-Dawley, Inc., Madison, WI) subjected to either dorsal ovariectomy or sham operation under general anesthesia. In each study ovariectomized animals were treated for 4 wk with continuous subcutaneous infusions of either IL-1 ra (Synergen Inc., Boulder, CO), IL-lra vehicle, BSA, or 10 ,ug/kg body wt per d 17# estradiol. Sham-operated animals were treated for 4 wk with IL-lra, BSA, or control vehicle. In study 1, (38) .
For cortical bone analysis, cross sections 200 Am thick were cut from the tibial diaphysis 15 mm from the proximal end using an Isomet low speed saw with a diamond wafer blade. The sections were ground to a thickness of 20-25 Aim and mounted unstained on glass slides for analysis of the percent labeled endocortical and periosteal surfaces under ultraviolet light (38) . Under transmitted light the same sections were used to quantify marrow area (the area within the endosteal surface of the specimen), cross-sectional bone area (the area within the periosteal surface of the specimen), cortical bone area (the area determined by subtracting marrow area from the cross-sectional area), and cortical thickness. All measurements were performed using a Bioquant Morphometry System (R&M Biometrics, Inc., Nashville, TN).
Pyridinoline crosslinks assay. The urinary excretion of pyridinoline crosslinks, a marker of bone resorption (39, 40), was measured 2 and 4 wk after surgery in urine samples collected between 2:00 and 6:00 p.m. using an ELISA kit developed by Metra Biosystems (Palo Alto, CA) (41) . Briefly, a l0-,l urine sample and 150 ,l of rabbit antipyridinoline antiserum were added to a pyridinoline-coated microplate and incubated overnight. After the plates were washed with PBS, 150 ,1 of goat anti-rabbit IgG alkaline phosphatase conjugate was added to each well. The unbound conjugate was then removed by washing and the enzyme activity measured~photometrically by adding an enzyme substrate and using a microplate reader at 405 nM. Results were expressed as nanomoles per millimole of urinary creatinine, as measured by a standard colorimetric technique. The intra-and the interassay variation of this method are < 9% and < 15%, respectively (42) .
Osteocalcin assay. Serum osteocalcin, a marker of bone formation (43), was measured 2 and 4 wk after surgery with a previously described radioimmunoassay method which makes use of an antibody highly specific for rat osteocalcin (44) . The sensitivity ofthis assay is 10 pg/ml. All reagents were purchased from Biomedical Technologies Inc. (Stoughton, MA).
IL-Ira assay. Serum levels of IL-1ra were measured at 2 and 4 wk oftreatment using a specific ELISA recently described (45) . The sensitivity of this assay is 8 pg/ml.
Cells cultures and IL-I assay. To investigate the effect of ovariectomy on the production of IL-l from bone marrow cells, additional groups of untreated 6-mo-old rats were subjected to ovariectomy or sham operation as described above and killed 2 and 8 wk after surgery. At sacrifice, femora were removed and dissected free ofadherent tissue, the bone ends were cut across the ephiphyses and the bone marrow cavity flushed with RPMI 1640 tissue culture medium supplemented with 10 U/ml heparin and 1 tg/ml DNAase. The bone marrow was fractionated on Ficoll Hypaque to prepare mononuclear cell cultures as described (21, 22) . The bone marrow mononuclear cells were seeded at 5 X 106 cells/ml and cultured for 24 h with or without the addition of 100 pg/ml LPS. IL-l bioactivity was measured in the 24-h culture media of the bone marrow mononuclear cells by assessing the increment in mitogen-induced proliferation of the helper T cell DlO.G4. 1 (DO0 cells) as previously described (21, 22). DO0 cell proliferation was converted to arbitrary units per milliliter ofIL-I activity by performing a log-logit transformation ofthe serial dilution curves and determining the dilution of the test sample that yielded a value corresponding to 50% ofthe standard IL-I maximum activity. The standard IL-I activity was arbitrarily set at 100 U/ml. The nature ofthe assayed material was confirmed as IL-I by demonstrating inhibition of the conditioned medium effect on the D10 cell proliferation in the presence of 50 ng/ml IL-lra.
Assessment ofserum neutralization activity. The presence ofbiologically active IL-lra in the serum of IL-lra-treated rats was determined by assessing the serum obtained from ovariectomized rats at the end of the 4-wk-long IL-lra treatment against IL-1 3 augmentation of mitogen-induced proliferation ofDO0 cells. Rat sera ( 12.5 p1) or IL-lra (2.5 ng) were serially diluted ( 1:2) and added to D10 cells seeded in 96-well plates. Recombinant human IL-lI3 (7.5 pg) was then added to each well. This concentration of IL-1# was selected because it induces 50% maximal augmentation in the D 10 cell proliferation assay. At the end of a 3-d culture period the Dl 0 cell proliferation was measured as described above. Results were expressed as percent inhibition of D10 cell proliferation.
Statistical analysis. 
Results
Ovariectomy increases the secretion ofIL-J from cultured bone marrow cells. Mononuclear cells cultured for 24 h in polystyrene plates with ordinary tissue culture media (which contains small amounts of LPS) express IL-l mRNA and secrete small quantities of IL-l (46, 47). In accordance with these published data, bone marrow cells from untreated sham-operated rats were found to secrete measurable amounts of IL-1 bioactivity into the 24-h culture medium (Table I) . When further stimulated with the addition of 100 pg/ml LPS, bone marrow cells secreted higher amounts ofIL-1 bioactivity which was neutralized by the addition of IL-lra to the assay system. 2 and 8 wk after surgery bone marrow mononuclear cells from ovariectomized rats produced higher amounts of IL-l bioactivity than the corresponding cells obtained from sham-operated animals rats (Table I) .
Serum from IL-ira-treated rats neutralizes IL-if3 in vitro. IL-lra, as measured by a specific ELISA, was not detectable in the serum of rats treated either with vehicle or estrogen. In contrast, rats treated with 2 mg/kg body wt per d IL-lra had serum IL-lra levels of 160.6±8.6 ng/ml at 2 wk of treatment and 213.4±14.9 ng/ml at 4 wk. When tested in a proliferation neutralization assay, the serum of rats treated with IL-lra for 4 wk inhibited IL-,#-induced augmentation ofD 10 cells proliferation in a manner similar to fresh recombinant IL-lra (Fig. 1 ). In these experiments parallel and dose-responsive inhibition curves of IL-l-induced augmentation of DO0 cell proliferation were obtained with IL-Ira and serum from IL-1 ra-treated rats.
The sample dilution containing either 3 ,ul ofserum (0.64 ng of IL-lra by ELISA) or 0.5 ng of fresh IL-lra per well inhibited about 50% ofthe IL-1 -induced augmentation ofproliferation. Figure 1 . Effect of serum from IL-lra-.treated rats on IL-IB-induced augmentation of DIO cell proliferation (mean±SEM). Sera (12.5 JI) obtained at the end of the treatment period from 14 ovariectomized rats treated with either IL-Ira (n = 7) or vehicle (n = 7) or fresh ILlra (2.5 ng) (n = 4) were serially diluted ( 1:2) and added to DO0 cells seeded in triplicate in 96-well plates. Recombinant human IL-D I (7.5 pg) was then added to each well. DIO cell proliferation was measured after a 3-d incubation, as described in Methods. Results (mean of three experiments) are expressed as percent inhibition of DIO cell proliferation. *P < 0.05, **P < 0.005, and ***P < 0.0001 compared to the other two groups.
These amounts of IL-Ira were -85 and 67 times the concentration of IL-I,8 used to stimulate the DO0 cells, respectively. Serum from vehicle-treated rats had no effect on IL-1 -induced augmentation ofproliferation. These findings demonstrate that a 4-wk treatment with human IL-lra did not induce the formation of rat anti-human IL-1 ra antibodies in an amount capable of blocking the biological effects of IL-lra.
Effect ofIL-l ra treatment on BMD. Fig. 2 shows the effect of IL-1ra treatment on BMD in ovariectomized rats. During the treatment phase of study 1 (Fig. 2 A) BMD decreased rapidly in BSA or vehicle-treated ovariectomized rats whereas no significant changes in BMD occurred in groups treated with 1 7fl-estradiol. In this study rats were treated with three doses of IL-lra. The lowest dose of IL-lra (0.4 mg/kg body wt per d) was ineffective, as the changes in BMD in this group and in the control groups were similar. In contrast, 2 and 10 mg/kg body wt per d of IL-1 ra were both effective, as the bone loss in these groups was lower (P < 0.05) than in either the vehicle or the BSA groups. Interestingly, the response to IL-1ra was more pronounced in the second 2 wk of treatment than in the first 2 wk. In fact, the change in BMD between the second and the fourth week of IL-1 ra treatment was not significant.
In the pretreatment phase of study 2 ( Fig. 2 B) BMD decreased significantly in all groups of ovariectomized rats. During the treatment phase of this study BMD continued to decrease rapidly in rats treated with BSA or vehicle alone whereas no additional bone loss occurred in the estrogen-treated rats. In study 2, IL-1 ra completely arrested ovariectomy-induced bone loss. As a result, during the treatment period ofthis study there was no significant bone loss in either the IL-1 ra or the estrogen treated rats (P < 0.05 compared to the vehicle or the BSA groups for both the estrogen and IL-I ra groups) and the BMD values at the end ofthe study were similar in the IL-I ra and the estrogen groups. Table II shows the effect of IL-1 ra treatment in sham-operated animals. In each ofthe two studies a small, nonsignificant decrease in BMD was observed over time in all groups ofshamoperated animals. These changes were similar in the vehicle, the BSA and the IL-1 ra groups, a finding indicating that IL-I ra specifically prevents the bone loss associated with ovariectomy.
At the end of each study the weight ofthe uterus was lower in ovariectomized rats treated with vehicle or IL-lra than in ovariectomized rats treated with estrogen or sham-operated rats treated with either vehicle or IL-1 ra. In contrast, no difference in uterine weight was found between estrogen treated ovariectomized rats and sham-operated rats (data not shown). These findings demonstrate the efficacy of the ovariectomy and suggest that IL-Ira has no estrogen-like effects.
Effect ofIL-i ra treatment on bone histomorphometry. In a preliminary study we determined that in rats of 6 mo of age, 8 wk are required for ovariectomy to induce a significant decrease in TBV, as assessed by histomorphometric analysis of distal femur metaphysis. For this reason, bone histomorphometry was used to analyze the effects ofIL-1 ra on bone volume and bone turnover in the femur metaphysis and tibial diaphysis of rats treated between weeks 4 and 8 after surgery (experiment 2). Specimens from an additional group ofuntreated rats killed 4 wk after ovariectomy were also analyzed and used as additional (baseline) controls. Moreover, since bone densitometry showed that ovariectomy causes a similar bone loss in rats treated with vehicle and BSA, quantification of histomorphometric indices was not performed in rats treated with BSA. Sham operation did not cause significant BMD changes in either of the two experiments. There were no significant differences between the vehicle-, and BSA-, and the IL-Ira-treated sham-operated rats. All experimental procedures and statistical analysis were conducted as described in Fig. 2 During the second month after ovariectomy TBV decreased at a low rate in the vehicle-treated ovariectomized rats. As a result, the difference in TBV between baseline controls (killed at week 4) and the vehicle group (killed at week 8) slightly miss significancy (P = 0.058) (Fig. 3 A) . However, at week 8 the vehicle-treated ovariectomized rats had a lower TBV than both the vehicle and the IL-lra-treated sham rats. These findings indicate that ovariectomy induced a significant loss oftrabecular bone and that a large part ofthis loss occurred in the first 4 wk after ovariectomy. Estrogen was effective in preventing TBV loss during the treatment period, as indicated by the finding ofa similar TBV in the estrogen-treated rats and the baseline control group. However, because ofthe small TBV loss in the vehicle group between weeks 4 and 8, at the end of the study TBV was not significantly higher in the estrogen group than in the vehicle group. Treatment with IL-Ira was also effective in preventing trabecular bone loss during the second month after ovariectomy, as demonstrated by the finding ofa higher TBV in the IL-I ra-treated group than in the baseline control group. Although this difference was not significant, as a result ofthe increase in TBV induced by IL-I ra between weeks 4 and 8, at the end ofthe study TBV was significantly higher in the IL-Ira group than in the vehicle-treated rats. Taken all together, these data suggest that IL-l ra was more potent than estrogen in preventing trabecular bone loss between weeks 4 and 8.
In vehicle-treated rats, ovariectomy was also associated with a significant increase in osteoclast number (Fig. 3 B) and osteoclast covered surfaces (Fig. 3 C) . The lack of a difference between the vehicle group and the baseline controls indicate that bone resorption increased mainly during the first 4 wk after ovariectomy. The increase in these two indices of bone resorption was equally prevented by either IL-1ra or estrogen. IL-I ra had no effect on TBV and indices of bone resorption in sham-operated rats.
The effect of IL-1 ra on trabecular bone formation was evaluated by measuring static and dynamic (tetracycline-based) indices. Although metaphyseal endocortical surfaces showed an amount of double-labeled surfaces sufficient for precise quantification of dynamic indices of bone formation, < 0.5% ofthe metaphyseal trabecular surface utilized for the histomorphometric analysis exhibited double-tetracycline labeling, a finding consistent with a low rate oftrabecular bone formation.
Although the small amount of double-labeled surfaces prevented a precise estimation of the rate of bone formation, the mineralized surface corresponded to the osteoid surface and estrogen, but not IL-1 ra or vehicle, appeared to decrease tetracycline-labeled trabecular surface (not shown). Analysis of static indices ofbone formation showed that in sham-operated rats the amount of osteoid surface and the osteoid thickness were small (Table III) in both the vehicle and IL-Ira treated rats. These findings are similar to those of Wronski et al. (48) and confirm that in aged rats bone formation takes place at a low rate. Although both indices increased slightly after ovariectomy, the differences were not significant. Moreover, neither IL-Ira nor estrogen treatment induced significant changes in these indices. Analysis of cortical bone (Table IV) by histomorphometry of tibial diaphysis harvested at week 8 revealed that ovariectomy had no significant effects on cortical bone area, cortical thickness, marrow area, and cross-sectional area. Moreover, although the finding of a small amount of double-labeled surfaces prevented us from accurately measuring endosteal and periosteal bone formation rate, there was sufficient single labeling to accurately measure the percentage of labeled surface, a dynamic index ofbone formation. We found that ovariectomy caused a significant increase in endosteal and periosteal labeled surfaces. Estrogen treatment between weeks 4 and 8 had no effect on static indices of bone and marrow areas. However, estrogen treatment induced a significant decrease in periosteal but not endosteal labeled surfaces. In contrast, IL-Ira had no effect on both static and dynamic indices.
Effect ofIL-i ra treatment on urinary excretion ofpyridinoline crosslinks and blood osteocalcin levels. Bone turnover is known to increase rapidly in response to estrogen withdrawal in both humans and rats (43) . Therefore, in order to investigate the effects of IL-I ra on the early changes in bone turnover induced by ovariectomy, the urinary excretion of pyridinoline crosslinks, a marker ofbone resorption ( 39, 40) , and the serum levels of osteocalcin, a marker of bone formation (43), were measured 2 and 4 wk after ovariectomy. At 2 wk after surgery, pyridinoline crosslink excretion and serum osteocalcin were both significantly higher in ovariectomized rats treated with vehicle than in sham-operated rats (Figs. 4 and 5) . At Figure 3 . Effect of IL-Ira treatment (mean±SEM) on TBV and histomorphometric indices ofbone resorption. Rats treated with either vehicle, IL-Ira or estrogen (n = 10 rats per group, randomly selected from the entire experimental group) between weeks 4 and 8 (study 2) were killed at the end of week 8 (solid bars) and compared to untreated rats (n = 6) killed 4 wk after ovariectomy (baseline controls; hatched bars). Distal femurs were harvested and processed as described in the methods. Percent trabecular bone volume is the percentage of marrow space occupied by trabecular bone. Osteoclasts are given as the number of osteoclasts per millimeter of trabecular bone surface. Percent osteoclast surface is the percentage of trabecular surface containing osteoclasts with "resorptive bays." aP < 0.05 compared to sham vehicle; bp < 0.05 compared to sham vehicle and sham IL-Ira; CP < 0.05 compared to ovx IL-Ira; dp < 0.05 compared to ovx baseline and ovx vehicle; eP < 0.05 compared to sham IL-Ira by Fisher protected LSD test. month after ovariectomy. Treatment with IL-I ra started at the time of surgery decreased pyridinoline excretion in ovariectomized rats (Fig. 4) . At both 2 and 4 wk after ovariectomy pyridinoline excretion was, in fact, lower in rats treated with either IL-I ra or estrogen than in those treated with vehicle. At 2 wk there was no difference between the IL-1ra and the estrogen-treated rats. At 4 wk, a time point when bone resorption was higher, pyridinoline excretion was lower in the estrogen than in the IL-ra-treated ovariectomized rats. In sham-operated rats IL-I ra treatment had no significant effects on pyridinoline excretion at both 2 and 4 wk.
The increase in serum osteocalcin induced by ovariectomy was prevented by estrogen treatment, but not by IL-1ra treatment. In ovariectomized rats at both 2 and 4 wk osteocalcin levels were, in fact, significantly lower in the estrogen-treated rats than in either the IL-lra or the vehicle group. In addition, IL-1ra treatment had no effect on osteocalcin levels in shamoperated rats.
Discussion
In this study we have found that treatment of ovariectomized rats with IL-Ira decreases bone resorption and blocks ovariectomy-induced bone loss.
At the doses used in this study IL-I ra competes specifically with IL-I and does not possess IL-1 agonistic effects (49) . In fact, infusions of IL-Ira up to 80 mg/kg body wt per d to healthy humans have been shown to cause no detectable biological effects (50) . The subcutaneous infusion of IL-Ira resulted in serum IL-Ira levels -10 times higher than those required to block 45Ca release in vitro from rat bone stimulated with 10 ng/ml of IL-I (33). Although there is no published information on either the amount ofIL-I released in vivo after ovariectomy or the level of IL-I receptors expressed in rat bone cells, the need for such a high concentration of IL-1 ra to affect bone loss in vivo is not surprising, as it is known that biological responses to IL-I can be observed when < 5% ofIL-1 receptors are occupied by IL-1 ( 30, 49) . Interestingly, the anti-IL-I activity of sera from rats treated with IL-I ra for 4 wk was similar to that of fresh IL-Ira. This indicates that the 4-wk-long infusion did not result in the production of rat anti-human IL-I ra antibodies in amounts sufficient to block the biological activity of IL-Ira or that IL-Ira treatment induced the formation of nonblocking antibodies.
The effects of IL-I ra on TBV and bone density were evaluated by bone histomorphometry and by dual-energy X-ray absorptiometry, a noninvasive technique which provides precise integrated measures of cortical and trabecular bone (35) . These measures were carried out in the distal femur, a weight bearing skeleton segment rich in trabecular bone. In agreement with earlier studies (51-53), both methods showed that ovariectomy causes a marked bone loss. However, because of the lower variability, a shorter follow-up was required to detect a significant bone loss with dual-energy X-ray absorptiometry than with bone histomorphometry. Our findings are consistent with those ofearlier studies demonstrating both the higher sensitivity for bone mass quantification and the higher correlation with density measurements by physical means, of X-ray absorptiometry than bone histomorphometry (54, 55) . The bone-sparing effect of IL-Ira was more potent in the second than in the first month after ovariectomy, a time when OVX VEHICLE bone marrow cell production of IL-I bioactivity was the highest. In fact, bone loss was decreased, but not completely arrested, when rats were treated with IL-Ira in the early postovariectomy period. In contrast, bone loss was completely arrested when rats were treated with IL-Ira during the second month after ovariectomy. These data suggest that the role of IL-I in conditioning the changes in bone remodeling induced by estrogen deficiency increases with the passage of time since ovariectomy. This hypothesis is further supported by the finding that in each study IL-1 ra was also more effective during the second 2 wk than in the first 2 wk of treatment. In study 1, the bone sparing effects of IL-Ira at 2 or 10 mg/kg body wk per d were similar. An insufficient block ofIL- 1 Figure 4 . Effect of IL-Ira treatment on the urinary excretion (mean±SEM) of pyridinoline crosslinks (n = 8 rats per group, randomly selected from the entire experimental group). The pyridinoline crosslinks/creatinine ratio (PYD/Cr) was determined in urine samples collected 2 and 4 wk after surgery as described in Methods. Rats were treated with IL-lra during the first 4 wk after surgery. *P < 0.05 compared to vehicle treated ovariectomized rats. **P < 0.05 compared to both vehicle-and IL-ira-treated ovariectomized rats, by To investigate the mechanism of the bone-sparing effect of IL-1 ra we have examined histomorphometric and biochemical indices of bone turnover. During the second month after ovariectomy IL-lra treatment resulted in a slight increase in TBV. In contrast, estrogen blocked, but did not reverse, trabecular bone loss. Interestingly, neither IL-Ira nor estrogen affected cortical bone area. These data suggest that at week 8 the IL-I raand the estrogen-treated rats had similar BMD values because the difference in trabecular bone density was too small to be detected by our densitometric technique, a method which is heavily influenced by cortical bone and provides an integrated measure of the density of the two skeleton envelopes.
Although we were unable to accurately quantitate trabecular bone formation, analysis ofcortical bone by bone histomorphometry and of serum osteocalcin levels indicated that estrogen, but not IL-Ira, prevented the increase in indices of bone formation which typically follows ovariectomy in rats (37, 56) . We recognize that the different effects of the two agents on bone formation should be interpreted with caution. However, one may speculate that estrogen modulates bone resorption via an IL-l-dependent pathway and bone formation via a distinct, IL-l-independent, mechanism.
Our findings also demonstrate that IL-Ira decreases bone resorption in a manner similar to estrogen replacement. Interestingly, the effect ofIL-I ra on pyridinoline crosslink excretion during the first month after ovariectomy was more potent than that observed in the same time period with BMD measurements. This is consistent with previous human studies demonstrating that biochemical markers of bone turnover do not faithfully reflect the rate of bone loss at the time of the marker measurement, but rather correlate moderately with BMD measurements (43) .
IL-Ira had no effect on the bone density and on the bone turnover of sham-operated rats, indicating that IL-lra specifically blocks estrogen-dependent bone loss. The data are also consistent with the lack ofpublished evidence for a role of IL-1 in physiologic bone remodeling.
Taken all together, our findings demonstrate that IL-I contributes to the pathogenesis ofpostovariectomy bone loss. However, the incomplete response to IL-1ra observed in the early postovariectomy period suggests that other factors may contribute to the bone loss induced by estrogen withdrawal. A likely candidate is IL-6. This cytokine is, at least in the mouse, regulated by estrogen (26) , and an increased production of IL-6 in the bone marrow ofovariectomized mice increases osteoclastogenesis in vitro ( 18) . Thus, since the secretion of IL-6 from stromal cells and bone cells is induced by both IL-1 and TNFa (26), our findings could, indeed, be explained by a persistent production of IL-6. Conversely, the similar response to estrogen and IL-1 ra in the second month after ovariectomy, suggests that the production of, or the response to, IL-6 or other cytokines produced independently of IL-I may decrease in the late postovariectomy period.
In conclusion, the present findings indicate that IL-1, or mediators induced by IL-1, play an important causal role in the mechanism by which ovariectomy induces bone loss in rats, especially following the early postovariectomy period. It will be interesting, therefore, to investigate whether IL-1ra has a practical role in the treatment of postmenopausal osteoporosis in humans.
